ArticleClinical endocrinology2025
Innovative Approaches to Improve the Success of Pituitary Surgery in Cushing's Disease: A Cost-Effectiveness Perspective.
Article in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePatients require additional treatment when pituitary surgery for Cushing's disease is unsuccessful. Exciting innovations in pituitary surgery bring hope for achieving better outcomes. Quantifying the potential value of these innovations using early health economic modelling can provide guidance throughout their development. The aim of this study was to explore the conditions for success of these innovations using cost-effectiveness analyses.
designThe model consists of a decision tree and state-transition model with a 10-year time horizon. PATIENTS: The model simulates the clinical management of patients with Cushing's disease and pituitary surgery as primary treatment. MEASUREMENTS: Model input was derived from literature and expert opinion. Model outcomes were incremental healthcare costs and incremental quality-adjusted life-years (QALY). We performed scenario analyses, including a headroom and threshold analysis, to determine the maximum innovation price for cost-effectiveness. Probabilistic sensitivity analysis and one-way sensitivity analyses were performed to address the impact of uncertainty on outcome parameters.
resultsThe headroom analysis showed that per patient 0.028 QALYs could be gained and 2082 euros could be saved over 10 years. With a willingness to pay of 80,000 euros, the maximum price of an innovation is 4288 euros (95% CI: 3377-5181) to reach cost-effectiveness. Sensitivity analyses showed that utility values mainly determined cost-effectiveness.
conclusionOur early health economic model exploring the conditions for success of innovations in pituitary surgery shows room for improvement, but also the importance of accurate health-related quality of life data to assess the economic value of innovations in individuals with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.